Skip to main content
Figure 2 | Breast Cancer Research

Figure 2

From: Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies

Figure 2

Kaplan–Meier curves for progression-free survival in patients with metastatic breast cancer given trastuzumab-based treatment. Curves were plotted for two groups of patients, those whose HER2/neu concentrations seen at 2 to 4 weeks of trastuzumab-based therapy were ≤ 77% of the baseline concentrations and those for whom it was >77% (median progression-free survival time 587 and 217 days, respectively) df = 1. HER, human-epidermal-growth-factor receptor.

Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us